Dacarbazine

Author: Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 22.04.2021

Dieser Artikel auf Deutsch

Synonym(s)

DTIC

Definition
This section has been translated automatically.

Antimetabolite, prodrug.

Half-life
This section has been translated automatically.

5 h

Indication
This section has been translated automatically.

Metastatic malignant melanoma as mono- or combination therapy, sarcomas, M. Hodgkin.

Dosage and method of use
This section has been translated automatically.

  • According to chemotherapy protocol:
    • monotherapy:
      • 200-250 mg/m2 KO/day IV, day 1-5, every 21-28 days.
      • 850-1200 mg/m2 KO/day i.v., day 1, every 21-28 days.
  • In combination therapies according to the following schemes:
    • BHD, BVD, BOLD, DVP, DBCT, DTIC-INFα, DTIC-IL2.

Remember! Women and men must use effective contraception during the therapy and until 6 months after the end of the therapy. In the case of high-dose chemotherapy, men should have a spermiogram before and after therapy and be made aware of the possibility of cryopreserving sperm!

Undesirable effects
This section has been translated automatically.

  • Cutaneous adverse reactions: photosensitivity, pruritus, erythema, allergic reactions.
  • Extracutaneous UAWs: BB changes, gastrointestinal disturbances, Budd-Chiari syndrome, renal damage, headache, flu-like symptoms, transaminase elevation.

Reminder. During therapy, regular checks of GOT and GPT as well as blood count!

In the event of a sudden increase in transaminases or eosinophilia > 30%, discontinue dacarbazine and administer glucocorticoids and heparin !

Interactions
This section has been translated automatically.

Cytostatic drugs lead to a mutual increase in toxicity.

Contraindication
This section has been translated automatically.

Pregnancy, lactation, leukopenia and/or thrombopenia, severe liver or kidney disease.

Preparations
This section has been translated automatically.

Detimedac

Literature
This section has been translated automatically.

  1. Hauschild A et al (2008) systemic therapy of melanoma. Current clinical studies. dermatologist 59: 484-492

Authors

Last updated on: 22.04.2021